NCT00400816View on ClinicalTrials.gov

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 17, 2008

Study Completion Date

January 6, 2016

Conditions
Central Nervous System TumorsBrain Tumor
Interventions
DRUG

temozolomide

Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]

Trial Locations (1)

44106-5065

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00400816 - Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma | Biotech Hunter | Biotech Hunter